BinaxNOW Rapid Antigen Test Performance Evaluated at Arizona Community Testing Sites

An evaluation study assessed the performance of the Abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection. The study was conducted at two community-based testing sites in Pima County, Arizona, involving persons presenting for testing. The specific sample size was not reported, and no comparator test was detailed in the available report.

The primary outcome was the performance of the BinaxNOW test. However, the main results, including sensitivity, specificity, exact numbers, effect sizes, confidence intervals, or p-values, were not reported. The direction of any findings was also not specified.

No information on safety, adverse events, or tolerability was provided. The report did not list specific study limitations, and funding sources or potential conflicts of interest were not disclosed. The practice relevance was not reported. Given the incomplete nature of this preliminary report, clinicians should await full, peer-reviewed publication of the methodology and results before drawing conclusions about test performance in community settings.